Raras
Buscar doenças, sintomas, genes...
Febre amarela
ORPHA:99829CID-10 · A95.0CID-11 · 1D47DOENÇA RARA

A febre amarela (FA), causada pelo vírus da FA, é uma doença zoonótica caracterizada por febre e sintomas constitucionais, com potencial de progredir para febre hemorrágica viral grave e fatal com choque e falência de múltiplos órgãos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A febre amarela (FA), causada pelo vírus da FA, é uma doença zoonótica caracterizada por febre e sintomas constitucionais, com potencial de progredir para febre hemorrágica viral grave e fatal com choque e falência de múltiplos órgãos.

Pesquisas ativas
13 ensaios
70 total registrados no ClinicalTrials.gov
Publicações científicas
8.476 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: A95.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
7 sintomas
🫃
Digestivo
6 sintomas
❤️
Coração
3 sintomas
🧠
Neurológico
2 sintomas
🫘
Rins
2 sintomas
🛡️
Imunológico
1 sintomas

+ 24 sintomas em outras categorias

Características mais comuns

90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Aumento do nível circulante de IgM
Muito frequente (99-80%)
90%prev.
Viremia
Muito frequente (99-80%)
90%prev.
Concentração elevada de alanina aminotransferase circulante
Muito frequente (99-80%)
90%prev.
Náusea
Muito frequente (99-80%)
55%prev.
Vômitos
Frequente (79-30%)
47sintomas
Muito frequente (5)
Frequente (18)
Ocasional (17)
Muito raro (7)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 47 características clínicas mais associadas, ordenadas por frequência.

FebreFever
Muito frequente (99-80%)90%
Aumento do nível circulante de IgMIncreased circulating IgM level
Muito frequente (99-80%)90%
Viremia
Muito frequente (99-80%)90%
Concentração elevada de alanina aminotransferase circulanteElevated circulating alanine aminotransferase concentration
Muito frequente (99-80%)90%
NáuseaNausea
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico8.476PubMed
Últimos 10 anos200publicações
Pico2026110 papers
Linha do tempo
2026Hoje · 2026🧪 2004Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado4
3Fase 34
2Fase 24
1Fase 13
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Febre amarela

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

6 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

70 ensaios clínicos encontrados, 13 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Ensaio randomizado
Timeline de publicações
3.835 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 3.835

#1

LRP8 is a functional receptor for yellow fever virus.

Nature microbiology2026 Mar 19

Yellow fever virus (YFV) is an arbovirus causing substantial human morbidity and mortality. The live-attenuated 17D strain serves as vaccine and is one of the most successful vaccines so far. Receptor usage between attenuated and pathogenic YFV strains remains unclear. Here we performed a barcoded, genome-wide human open-reading frame library screen and identified LRP8 (also named APOER2) as a receptor for YFV. We show that LRP8 expression increases YFV infection (17D and two clinical strains, BJ01 and Asibi) in cell lines by promoting entry. Adeno-associated virus-mediated expression of human LRP8 in mouse liver aggravates infection and pathology of the clinical strain BJ01. LRP8 knockdown decreases YFV infection in brain cells, primary human hepatocytes and mosquitoes. LRP8 directly interacts with YFV 17D particles via the viral envelope protein. A soluble LRP8 decoy protein can block YFV 17D and BJ01 infection. Our findings provide insights for understanding YFV entry, tropism and pathogenesis.

#2

Evolution and spillover dynamics of yellow fever at the forest-urban interface in Brazil.

Nature microbiology2026 Mar 11

Yellow fever virus (YFV) continues to threaten human and wildlife populations in the Americas, yet its transmission at the forest-urban interface remains unclear. Here we integrate ground- and canopy-level mosquito surveillance, systematic monitoring of non-human primate carcasses and viral metagenomics to describe the dynamics of a sylvatic YFV outbreak in a 186-hectare Atlantic Forest fragment embedded within metropolitan São Paulo, Brazil, between 2017 and 2018. Our analyses reveal that transmission was primarily driven by a single genetic cluster introduced during a period of high abundance of the main vector, Haemagogus leucocelaenus mosquitoes. A near-complete hepatitis A virus genome was detected in a YFV-infected howler monkey, suggesting potential co-infections at the human-wildlife interface. Phylogenetic and epidemiological modelling estimated a basic reproduction number, R0, for sylvatic yellow fever of 8.2 (95% CI 5.1-12.2), substantially higher than previous estimates for urban outbreaks. Our findings demonstrate that multisource surveillance could provide actionable early warnings in regions at risk for zoonotic spillover.

#3

Dose-dependent immune modulation in arboviral coinfections among febrile patients.

Frontiers in cellular and infection microbiology2026

Arboviruses pose substantial diagnostic and public health challenges in tropical regions where multiple pathogens co-circulate. Nigeria, with diverse ecological zones and limited surveillance infrastructure, represents a critical nexus for arboviral transmission, yet comprehensive data on seroprevalence, coinfection dynamics, immune modulation, and viral genetic diversity remain scarce. We conducted cross-sectional surveillance across three Nigerian ecological zones from January 2019 to December 2023. Sera from 871 participants were tested for IgG and IgM antibodies to dengue virus (DENV), chikungunya virus (CHIKV), Zika virus (ZIKV), yellow fever virus (YFV), West Nile virus (WNV), and Rift Valley fever virus (RVFV) using immunoblot assays. A stratified subset (n=300) underwent cytokine profiling for interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and interleukin-10 (IL-10). IgM-positive samples underwent RT-PCR confirmation with genotype assignment through sequence comparison against GenBank reference strains. Overall IgM seropositivity indicating recent infection was 86.8% (756/871), with DENV most prevalent (59.6%; 95% CI: 56.3-62.8%), followed by CHIKV (49.4%), YFV (48.3%), ZIKV (19.7%), WNV (3.4%), and RVFV (2.3%). Coinfection with two or more arboviruses was detected in 61.2% (533/871) of participants. Seropositivity was highest in the tropical rainforest zone (94.2%) compared with Guinea savanna (84.5%) and Sudan savanna (80.4%; χ²=31.8, p<0.001). Cytokine profiling revealed significantly elevated concentrations of IL-6, TNF-α, IFN-γ, and IL-10 in dual and triple infections compared with mono-infections (all p<0.001), demonstrating dose-dependent immune modulation. All four DENV serotypes were identified, with DENV-2 predominating (59.9%). Molecular characterisation confirmed circulation of CHIKV East/Central/South African genotype (82.1%), DENV-2 Cosmopolitan genotype, and both African (71.2%) and Asian (28.8%) ZIKV lineages, with study sequences showing >99% nucleotide identity to established reference strains. These findings reveal extraordinarily high levels of arboviral infection and coinfection across Nigerian ecological zones. The dose-dependent cytokine elevation in coinfections suggests distinct immunopathological mechanisms. These data underscore the urgent need for multiplex diagnostics, genotype-specific monitoring, and climate-informed vector control strategies.

#4

Yellow fever in Latin America and the escalating risks in a changing eco-epidemiological landscape: a review.

Lancet regional health. Americas2026 Apr

Yellow fever (YF) remains a major public health concern in Latin America. We characterise the early-2025 outbreak, compare it with prior waves-especially Southeast Brazil (2016-2018)-and examine environmental, structural, and policy-related drivers. We reviewed regional surveillance data and mortality records from January to April 2025, comparing them to historical outbreak data. Case fatality rate (CFR), geographic spread, and population vulnerability patterns were analyzed. We also reviewed published literature and health alerts to contextualize contributing factors. In 2025, 301 confirmed cases and 124 deaths were reported (CFR 41.1%), mostly in Bolivia, Brazil, Colombia, and Peru, concentrated among unvaccinated populations at the forest-urban interface. Transmission remains sylvatic, but peri-urban spillover risk is rising. Deforestation, climate variability, cross-border migration, and political instability heighten vulnerability; surveillance is fragmented and vaccine uptake insufficient in high-risk groups. YF is re-emerging through intertwined biological, ecological, and socio-political forces. Preventing another large-scale epidemic requires strengthened, integrated surveillance, including Non-Human Primates (NHP) epizootics, equity-centred immunisation in remote areas, and coordinated regional action focused on prevention, early detection, and health-system resilience. La fiebre amarilla (FA) continúa siendo un importante problema de salud pública en América Latina. Caracterizamos el brote de inicios de 2025, lo comparamos con olas previas—en especial el del sudeste de Brasil (2016–2018)—y examinamos determinantes ambientales, estructurales y de política sanitaria. Revisamos datos regionales de vigilancia y registros de mortalidad de enero a abril de 2025, comparándolos con series históricas, particularmente el brote del sudeste de Brasil (2016–2018). Se analizaron las tasas de letalidad por casos (CFR), la expansión geográfica y los patrones de vulnerabilidad poblacional. También revisamos literatura publicada y alertas sanitarias para contextualizar los factores contribuyentes. En 2025 se notificaron 301 casos confirmados y 124 defunciones (CFR 41.1%), sobre todo en Bolivia, Brasil, Colombia y Perú, concentradas en poblaciones no vacunadas en la interfaz selva–urbana. La transmisión sigue siendo selvática, pero aumenta el riesgo de desbordamiento periurbano. La deforestación, la variabilidad climática, la migración transfronteriza y la inestabilidad política incrementan la vulnerabilidad; la vigilancia es fragmentada y la cobertura vacunal insuficiente en grupos de alto riesgo. La FA está reemergiendo por fuerzas biológicas, ecológicas y sociopolíticas entrelazadas. Prevenir otra epidemia de gran escala exige vigilancia fortalecida e integrada (incluidas epizootias en primates no humanos), inmunización centrada en la equidad en áreas remotas y acción regional coordinada enfocada en la prevención, la detección temprana y la resiliencia de los sistemas de salud. A febre amarela (FA) continua sendo uma grande preocupação de saúde pública na América Latina. Caracterizamos o surto inicial de 2025, comparamos com ondas anteriores—especialmente no sudeste do Brasil (2016–2018)—e examinamos os fatores ambientais, estruturais e relacionados a políticas. Revisamos dados regionais de vigilância e registros de mortalidade de janeiro a abril de 2025, comparando-os com dados históricos de surtos. Foram analisadas as taxas de letalidade por casos (CFR), a disseminação geográfica e os padrões de vulnerabilidade populacional. Também revisamos literatura publicada e alertas de saúde para contextualizar os fatores contribuintes. Em 2025, foram reportados 301 casos confirmados e 124 mortes (CFR 41.1%), principalmente na Bolívia, Brasil, Colômbia e Peru, concentrados em populações não vacinadas na interface floresta-urbana. A transmissão permanece silvestre, mas o risco de transbordamento periurbano está aumentando. A desflorestação, a variabilidade climática, a migração transfronteiriça e a instabilidade política aumentam a vulnerabilidade; a vigilância é fragmentada e a adesão à vacina insuficiente em grupos de alto risco. A FA está reemergindo por forças biológicas, ecológicas e sociopolíticas interligadas. Prevenir outra epidemia em grande escala requer vigilância fortalecida e integrada, incluindo epizootias em primatas não humanos (PNH), imunização centrada na equidade em áreas remotas e ação regional coordenada focada na prevenção, detecção precoce e resiliência dos sistemas de saúde.

#5

Spatial and social determinants of the 1857 yellow fever epidemic in Lisbon.

PLoS neglected tropical diseases2026 Mar

Despite the availability of a highly effective vaccine, yellow fever virus (YFV) is still endemic in 47 countries globally. Although disease due to YFV was first recorded in 1635, factors contributing to its spread remain poorly understood today. Using archival data from the nineteenth century, we digitalised and mapped the 1857 yellow fever (YF) epidemic in Lisbon, Portugal, to understand how transmission dynamics and spatial and environmental characteristics led to disparities in health outcomes between sociodemographic groups. We modelled the basic and effective reproduction number (R0 and Rt) and found that transmission dynamics throughout this pre-vaccination era epidemic are consistent with prevailing estimates (R0 ≃ 5). Transmission peaked at the end of October 1857 when YF was declared an epidemic, then declined until January 1858. YFV killed 4.2% of the population with infection attack rates ranging between 10.3-13.5%. Out of the 34 parishes in urban Lisbon, our hotspot analysis identified 15 statistically significant high-risk parishes near the coastline. Our maps, combined with a digital terrain model, show that the highest number of deaths occurred within connected streets confined in low-elevation built-up areas with homes. We discuss the potential role of wind and temperature in aiding mosquito dispersal across Lisbon, which were believed as the main historical environmental drivers of YF. More people died at home than in hospitals, and although working-aged men accounted for most fatalities, the highest probability of death was found among women working at home. Our study highlights the role of human-environment interactions in shaping a historical YF epidemic in a pre-vaccination urban setting and enhances our understanding of modern-day transmission dynamics.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC4.672 artigos no totalmostrando 198

2026

Unique aspects of the acute kidney injury associated with infections in the tropics: presentation, challenges and opportunities.

Kidney international
2026

Metagenomic surveillance of zoonotic yellow fever and spillover dynamics at a forest-urban interface.

Nature microbiology
2026

LRP8 is a functional receptor for yellow fever virus.

Nature microbiology
2026

Reemergence of yellow fever in Venezuela, 2025/2026.

New microbes and new infections
2026

When yellow fever silenced the forest: Ecological collapse and reduced malaria transmission in the Rio de Janeiro Atlantic Forest, Brazil.

One health (Amsterdam, Netherlands)
2026

Safety of Live and Live-Attenuated Vaccines in Patients Receiving Biologics and Small-Molecule Therapies for Dermatologic Diseases: A Systematic Review.

The Australasian journal of dermatology
2026

A cohort study of the duration of immunity to yellow fever after 4 years of primary vaccination in children and adults.

Transactions of the Royal Society of Tropical Medicine and Hygiene
2026

Soft selective sweeps predominate in the yellow fever mosquito Aedes aegypti.

Molecular biology and evolution
2026

Evolution and spillover dynamics of yellow fever at the forest-urban interface in Brazil.

Nature microbiology
2026

Entomo-virological investigation during the epizootic outbreak of sylvatic yellow fever in Rio Grande do Sul, Brazil, between 2021 and 2022.

Memorias do Instituto Oswaldo Cruz
2026

Prioritisation and risk ranking of epidemic-prone diseases for emergency preparedness and response in Eastern Africa using a multi-criteria decision analysis framework, 2023.

Journal of public health in Africa
2026

Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications.

Journal of public health in Africa
2026

Dose-dependent immune modulation in arboviral coinfections among febrile patients.

Frontiers in cellular and infection microbiology
2026

Yellow fever in Latin America and the escalating risks in a changing eco-epidemiological landscape: a review.

Lancet regional health. Americas
2026

Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008-2022).

Pharmacoepidemiology and drug safety
2026

Time for a New Yellow Fever Vaccine.

The Journal of infectious diseases
2026

Spatial and social determinants of the 1857 yellow fever epidemic in Lisbon.

PLoS neglected tropical diseases
2026

Yellow fever beyond the Amazon: surveillance challenges and the role of Callithrix spp. in sylvatic cycles in Brazil.

Lancet regional health. Americas
2026

Clashing in Murky Waters: On Amphibian Mosquito Suppression.

Ecology and evolution
2026

Mitochondrial COI gene based population genetic structure and diversity of Aedes aegypti populations across diverse climatic regions of India.

Acta tropica
2026

Yellow fever in older populations: Marked age- and sex-based disparities in case-fatality rates in Colombia, Brazil, and Peru.

Travel medicine and infectious disease
2026

Entomological surveillance of malaria vector: species, behaviors, and insecticide resistance in southern and central Benin.

BMC infectious diseases
2026

Computational Insights into the Structural Dynamics of the E Protein's DIII Domain in Brazilian Yellow Fever Virus: Implications of Amino Acid Variations on Protein Plasticity and Potential Impact on Vaccine Efficacy.

ACS omega
2026

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro.

Antiviral research
2026

Histone Deacetylases Are Required for Aedes aegypti Female Reproduction and Embryonic Development.

Archives of insect biochemistry and physiology
2026

Aedes aegypti Hsp70 has enhanced ATPase and protein protection under oxidative stress.

International journal of biological macromolecules
2026

Artificial light at night as a potential driver of Aedes aegypti establishment in arid cities: insights from Las Vegas.

Journal of medical entomology
2026

1'- and 4'-Cyano Modified Adenosine Analogs Against Prototypic Flavivirus RNA-Dependent RNA Polymerases.

Viruses
2026

Next-Generation HIV-1 Therapeutics in Co-Endemic Settings.

Biomedicines
2026

Cytokine-based rapid process control of live virus production: MCP-1 as a cross-family biomarker in Vero cells.

Journal of virological methods
2026

Metabolic quiescence of naive-like memory T cells precedes and maintains antigen-specific T cell memory.

Nature immunology
2025

[A brief history and significance of the Czechoslovak army's Antiviral Serum Bank].

Klinicka mikrobiologie a infekcni lekarstvi
2026

Preliminary estimation of the basic reproductive number of yellow fever in Colombia, 2024-2026.

New microbes and new infections
2026

Integrated In Silico, In Vivo, and Deep Learning Approaches in the Discovery of Novel Candidate Molecules for Aedes aegypti Control.

Archives of insect biochemistry and physiology
2026

Metagenomic surveillance of undiagnosed febrile illness in Nigeria does not reveal the etiological agent for most patients.

bioRxiv : the preprint server for biology
2026

Diurnal fluctuating temperature and larval resource level interact to influence the life history and behaviour of disease-transmitting mosquitoes.

Parasites &amp; vectors
2026

Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial.

Vaccine
2026

Genomic characterization of Sabiá virus in Brazil, 2019-2020: Implications for diagnostics, virus evolution, and receptor binding.

PLoS neglected tropical diseases
2026

Entomological investigation of the 2023 chikungunya outbreak in Pouytenga, Burkina Faso, highlights the virus circulation in Aedes aegypti.

Current research in parasitology &amp; vector-borne diseases
2026

(Sero)prevalence of (re)emerging major arbovirus infections in Africa: a systematic review and meta-analysis protocol.

Systematic reviews
2026

Tolerance to persistent cell-fusing agent virus infection in Aedes aegypti mosquitoes correlates with maintenance of lipid reserves.

BMC biology
2026

Pulmonary Complications in Fatal Yellow Fever, Brazil, 2017-2019.

Emerging infectious diseases
2026

Yellow fever virus resurgence in Sao Paulo State, Brazil, 2024-2025.

Revista do Instituto de Medicina Tropical de Sao Paulo
2025

An integrated surveillance in Zhejiang Province: ecological and pathogen survey of vectors and reservoir hosts in 2024.

Frontiers in veterinary science
2026

Molecular Mechanisms of Antibody-Dependent Enhancement of Viral Infection.

Biochemistry. Biokhimiia
2026

Global trends of pandemic-prone and epidemic-prone disease outbreaks in 2024.

BMJ global health
2026

Human genetics of susceptibility to live-attenuated viral vaccines.

Current opinion in virology
2025

Rural Inhabitants' Perception-Induced Immunisation Status: The Case of Yellow Fever Vaccination in the Ashanti Region of Ghana.

Rwanda journal of medicine and health sciences
2026

Bacterial community structure and diversity of common mosquito species in Chengdu: Insights from PacBio third-generation sequencing and public health implications.

PLoS neglected tropical diseases
2026

A Replication-Competent Flavivirus Genome with a Stable GFP Insertion at the NS1-NS2A Junction.

Biology
2026

Sabethes mosquitoes (Diptera: Culicidae) associated with bamboo internodes in Pariquera-Açu and Cananeia, São Paulo State, Brazil.

Revista da Sociedade Brasileira de Medicina Tropical
2026

New insights into an old vaccine: potency and breadth of neutralizing antibodies elicited by the yellow fever vaccine 17D are boosted by heterologous Orthoflavivirus infection.

The Journal of infectious diseases
2026

Endemicity of a Yellow Fever Virus Strain Revealed by Entomological Surveillance in Southeastern Senegal.

The American journal of tropical medicine and hygiene
2026

Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.

The American journal of tropical medicine and hygiene
2026

Antagonism of RNA silencing in the yellow fever mosquito, Aedes aegypti, by the nsP2 protein of the prototype alphavirus.

Proceedings of the National Academy of Sciences of the United States of America
2026

Harnessing insect-derived oils for enhanced efficacy of plant-based repellents against disease-transmitting mosquitoes.

Scientific reports
2026

Technical validation and implementation of a multiplex real-time PCR for differential diagnostic detection of Zika virus, yellow fever virus, dengue virus and chikungunya virus (ZYDC-PCR).

BMC infectious diseases
2026

Pyrethroids and organophosphate resistance in Aedes aegypti (Diptera: Culicidae) and their underlying mechanisms.

Parasites &amp; vectors
2026

Molecular detection of insecticide resistance markers in Aedes aegypti (Diptera: Culicidae) populations from Haiti.

Journal of medical entomology
2025

Review of selected mosquito-borne diseases: arboviruses (dengue, chikungunya, Zika, West Nile, Japanese encephalitis, yellow fever) and parasitic diseases (malaria, lymphatic Filariasis).

Frontiers in public health
2026

Global epidemiology and evolutionary dynamics of arboviruses: A systematic review of surveillance, control strategies, and emerging threats.

Dialogues in health
2025

The spread of infectious diseases in migration routes between caravans and resident communities: Modelling yellow fever in Central America.

The journal of climate change and health
2026

Yellow fever re-emergence in Tolima, Colombia 2024-25: an eco-epidemiological study.

medRxiv : the preprint server for health sciences
2026

Development and validation of a sample-to-result real time multiplex RT-PCR test for human African trypanosomiasis and arboviral febrile illnesses in the Democratic Republic of the Congo.

BMC infectious diseases
2026

The L1014F Kdr mutation is associated with a higher prevalence and load of the Plasmodium-blocking symbiont Microsporidia MB In Anopheles Gambiae s.l. In Benin.

BMC microbiology
2026

Surveillance Service of Yellow Fever in Non-Human Primates in the Federal District, Brazil, 2008-2022.

Revista da Sociedade Brasileira de Medicina Tropical
2026

Distribution of yellow fever vectors in a disease-free area of Northeast Brazil.

Revista da Sociedade Brasileira de Medicina Tropical
2026

The impact of maternal flavivirus infections on fetal neurological outcomes: a scoping review.

Virology journal
2026

Review of mosquitoes in Ireland and of relevant mosquito-borne pathogens.

Irish veterinary journal
2026

Entomo-virological investigation in urban forest fragments and intradomiciles during a dengue outbreak in Salinas, MG, Brazil.

Memorias do Instituto Oswaldo Cruz
2026

Strengthening Arboviral Epidemic Response Through Entomological Surveillance: Insights from Bobo-Dioulasso, Burkina Faso.

Current issues in molecular biology
2026

Auto-Abs against type I IFNs: Strong, common, and global determinants of severe arboviral diseases.

Journal of human immunity
2026

Structural genomics sheds light on protein functions and remote homologs across the insect tree of life.

Cell research
2026

Thermal stress responses on developmental time, survival, and wing morphometrics in desert and coastal strains of Aedes aegypti (Diptera: Culicidae) from India.

Acta tropica
2026

Human autoantibodies against type I interferons in severe viral disease.

Current opinion in virology
2026

The Yellow Fever Vaccine Journey: Milestones and Future Directions.

Vaccines
2026

Temporal and Geographical Patterns of Pacific Arboviral Vectors on Ebeye, Republic of the Marshall Islands: Insights from a Longitudinal Entomological Study.

Pathogens (Basel, Switzerland)
2026

Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations.

International journal of molecular sciences
2026

Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research.

International journal of molecular sciences
2026

NUP98 regulates orthoflavivirus replication through interaction with vRNA and can be targeted for antiviral purposes.

Nucleic acids research
2026

Occupational Infection Prevention Among Nurses and Laboratory Technicians Amidst Multiple Health Emergencies in Outbreak-Prone Country, D.R. Congo.

Tropical medicine and infectious disease
2026

Cryopreservation of Anopheles gambiae Larvae.

Advanced biology
2026

Impact of the COVID-19 pandemic on travel medicine services in Taiwan, 2019-2022.

Travel medicine and infectious disease
2026

Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis.

Proceedings of the National Academy of Sciences of the United States of America
2026

From pandemic influenza to novel coronaviruses: emerging infectious diseases of the 21st century.

Diagnostic microbiology and infectious disease
2026

Estimating the impact of decreasing vaccination response times for outbreaks of vaccine-preventable diseases in low- and middle-income countries.

BMC global and public health
2026

Lipid Metabolism in Insect Vectors of Diseases.

Advances in experimental medicine and biology
2026

Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.

Lancet (London, England)
2026

Yellow fever vaccine minimum fractional dosing does not extend to infants.

Lancet (London, England)
2026

Preparation and application of YFV-17D-derived Anterograde Trans-neuronal Viral Vectors for Neuroscience Research.

bioRxiv : the preprint server for biology
2025

Spillover risk for yellow fever virus is amplified by forest-urban interface in the Amazon.

Biology letters
2026

Systematic review of Aedes aegypti control trials suggests publication bias related to author disclosure of conflicts of interest.

PLoS neglected tropical diseases
2026

RDA-PSO: A Computational Method to Quantify the Diffusive Dispersal of Insects.

Bulletin of mathematical biology
2026

Entomological surveillance in active dengue transmission areas of Santo Domingo de los Tsáchilas - Ecuador: Epidemiological importance of Aedes aegypti and the recent establishment of Aedes albopictus.

Acta tropica
2026

Metagenomic Exploration of the Bacteriome Reveals Natural Wolbachia Infections in Yellow Fever Mosquito Aedes aegypti and Asian Tiger Mosquito Aedes albopictus.

Current microbiology
2025

Involvement of Multiple Ion Channels and Receptors in Mediating the Insecticidal and Repellent Actions of Limonene.

International journal of molecular sciences
2026

Molecular diagnosis of arboviruses (dengue, Chikungunya, yellow fever, Rift Valley fever, Mayaro, West Nile, and Zika viruses) in non-malaria acute febrile illnesses in Kenya's Garissa County, July 2023, and Mombasa County, July 2024.

BMC infectious diseases
2026

Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report.

Vaccine
2026

Arboviruses circulation in Guinea: Overview and perspectives for public health.

PLoS neglected tropical diseases
2025

Insecticide resistance dynamics in Aedes mosquitoes in Ghana.

GigaByte (Hong Kong, China)
2025

Spatial and temporal distribution of Culex and Aedes mosquitoes in Ghana.

GigaByte (Hong Kong, China)
2026

A case of disseminated intravascular coagulation by leptospirosis during the ongoing yellow fever outbreak in Colombia.

New microbes and new infections
2026

Platforms to Evaluate Flavivirus-Induced Immunoinflammatory Responses and Their Pathogenesis.

Methods in molecular biology (Clifton, N.J.)
2025

Flavivirus NS1-triggered endothelial dysfunction promotes virus dissemination.

PLoS pathogens
2025

Viral hepatitis as a differential diagnosis of yellow fever suspected cases in Cameroon: Prevalence and molecular characterization.

IJID regions
2025

Development and Application of a Rapid Field Detection Technology for DENV-2 Based on the HUDSON Nucleic Acid Extraction-Free/RT-RAA/CRISPR-Cas12a System.

Viruses
2025

Monitoring Dengue Virus in Aedes aegypti to Improve Dengue Surveillance and Control in Puerto Rico.

Viruses
2025

Utility of TaqMan Array Cards for detection of acute febrile illness etiologies in patients suspected of viral hemorrhagic fever infections.

BMC infectious diseases
2025

Insecticide-treated screening of windows for household protection against insecticide-resistant Anopheles gambiae sensu lato in Côte d'Ivoire: a semi-field trial.

Parasites &amp; vectors
2025

Rapid virus-free production of recombinant yellow fever virus envelope protein and its in-depth biophysical analysis.

Scientific reports
2026

Challenges in insecticide resistance management: Implications of alternating selection in the yellow fever mosquito, Aedes aegypti.

Pesticide biochemistry and physiology
2025

Systematic Determinants of Global COVID-19 Burden: Longitudinal Time-Series Analysis Using Big Data-Driven Artificial Intelligence.

Journal of medical Internet research
2025

Exposure to 5G-NR electromagnetic fields affects larval development of Aedes aegypti mosquito.

Scientific reports
2025

Vertical transmission of mosquito microbiota and its effects on offspring development.

bioRxiv : the preprint server for biology
2026

Plaque reduction neutralization test (PRNT50) for the detection of anti-yellow fever antibodies from clinical samples.

Vaccine
2025

Serologic Evidence of Circulation of Six Arboviruses (Dengue Virus, Chikungunya Virus, Zika Virus, Rift Valley Virus, Yellow Fever Virus, Crimean-Congo Hemorrhagic Fever Virus) in Four Regions of Burkina Faso, West Africa.

Tropical medicine and infectious disease
2025

Intensive Therapeutic Plasma Exchange for Severe Yellow Fever: What Is the Evidence? Comment on Ho et al. Intensive Therapeutic Plasma Exchange-New Approach to Treat and Rescue Patients with Severe Form of Yellow Fever. Trop. Med. Infect. Dis. 2025, 10, 39.

Tropical medicine and infectious disease
2025

[Presence of Aedes aegypti in a high altitude area in Bolivia].

Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)
2025

Transposable elements in the transcriptome of Aedes (Stegomyia) aegypti (Linnaeus, 1762).

Medical and veterinary entomology
2026

Targeting Yellow-Fever Virus: Development of a specific aptamer to NS1 protein.

Journal of virological methods
2025

Timeliness of yellow fever specimen collection and transport in Ghana, 2018-2022.

PLOS global public health
2025

Development of a simple trap using widely available materials for collecting immature Sabethines (Diptera: Culicidae) and first records of Sabethes batesi and Wyeomyia nigritubus in Sergipe, Brazil.

Revista da Sociedade Brasileira de Medicina Tropical
2025

In vivo risk assessment of yellow fever virus transmission through breastfeeding, and mechanistic insights.

The Journal of infectious diseases
2025

Evaluating the role of observational uncertainty in climate impact assessments: Temperature-driven yellow fever risk in South America.

PLOS climate
2025

A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial.

Trials
2025

Expert consensus on vaccination as a primary prevention strategy for women of reproductive age, pregnant, or adulthood.

Revista colombiana de obstetricia y ginecologia
2025

Reemergence of yellow fever virus in forest and periurban settings in Brazil.

Communications medicine
2025

Differences in Genetic Diversity between Early Isolates of Yellow Fever Virus Genotypes.

Emerging microbes &amp; infections
2025

Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates.

Nature communications
2025

Reemergence of Yellow Fever, Magdalena Valley, Colombia, 2024-2025.

Emerging infectious diseases
2025

Chemometric Methods Applied to Infrared and Raman Spectroscopy for Arboviruses Diagnosis: A Systematic Review With Meta-Analysis.

Analytical science advances
2025

Yellow Fever Virus in Aedes albopictus Mosquitoes from Urban Green Area, São Paulo State, Brazil.

Emerging infectious diseases
2025

Strategic positioning of immunization at the heart of Africa's health and development agenda.

Human vaccines &amp; immunotherapeutics
2025

Pharmacovigilance assessment of adverse events following yellow fever vaccination: Disproportionality analysis of VAERS reports, 2015-2025.

Human vaccines &amp; immunotherapeutics
2025

Respiratory symptom burden, vaccination coverage, and preventive health practices among Sudanese Hajj pilgrims who traveled by sea.

Frontiers in public health
2026

Pickpocket315 affects male mating behavior in the yellow fever mosquito Aedes aegypti.

G3 (Bethesda, Md.)
2025

Potential distribution of Aedes vittatus as an invasive species in North America.

PloS one
2025

Sec61 translocon inhibitor flavitransin blocks selectively dengue virus polyprotein insertion in the ER with pan-orthoflavivirus antiviral potency.

Cell reports
2025

Spatiotemporal dynamics and determinants of yellow fever outbreaks in 21st century Brazil: an ecological study.

Transactions of the Royal Society of Tropical Medicine and Hygiene
2025

Yellow fever mortality in Brazil: an age-period-cohort study.

Revista de saude publica
2025

[Mosquito Surveillance at Airports and Seaports to Prevent and Control Emerging Mosquito-borne Diseases in the Republic of Korea, 2024].

Jugan geon-gang gwa jilbyeong
2025

[Mosquito Surveillance at Airports and Seaports to Prevent and Control Emerging Mosquito-borne Diseases in Korea, 2023].

Jugan geon-gang gwa jilbyeong
2025

[Identification of Culex quinquefasciatus Highlights the Need for Strengthened Vector Mosquito Surveillance in the Republic of Korea].

Jugan geon-gang gwa jilbyeong
2025

Beyond dengue and Oropouche: The urgent need for yellow fever preparedness in Cuba.

New microbes and new infections
2026

Larvicidal efficacy of Varronia curassavica leaf phytochemicals against Aedes aegypti: anatomical, histological and cytotoxic analyses.

Pesticide biochemistry and physiology
2025

Outbreaks and incidence of vector-borne diseases in Colombia (2007-2024): Impact of climate change and deforestation.

Biomedica : revista del Instituto Nacional de Salud
2026

Update on emerging and re-emerging vector-borne diseases.

The American journal of the medical sciences
2025

Standardized Diagnostic Assays for Omsk Hemorrhagic Fever Virus.

Pathogens (Basel, Switzerland)
2025

The Use of Disabled Insecticidal Proteins (DIPs) to Investigate the Interaction Between Aedes aegypti-Active Toxins from Bacillus thuringiensis.

Insects
2025

Highly Sensitive Si-Based Electrolyte-Gated Transistor Array for Multiplexed Detection of Arboviruses.

Micromachines
2025

Yellow fever vaccination coverage and knowledge, attitudes and practices: a cross-sectional study during an epizootic event in São Sebastião, Federal District, 2020.

Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil
2026

Travel After Transplant: Demographics, Travel Trends, and Vaccination Practices of US Immunocompromised Travelers.

Transplantation
2025

Development and application of a PCR-RFLP assay revealing widespread distribution of the pyrethroid resistance-associated VGSC V1016G mutation in Aedes albopictus from Guangyuan City, Sichuan Province of China.

Parasites &amp; vectors
2025

Seroepidemiological Investigation of Arboviruses in Callithrix jacchus in Sergipe, Brazil.

EcoHealth
2025

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses.

Journal of visualized experiments : JoVE
2026

Dengue in deployed military personnel, 1905-2024: a systematic review of incidence, diagnostics and prevention.

Journal of travel medicine
2025

Mimicry in the Bite: Shared Sequences Between Aedes aegypti Salivary Proteins and Human Proteins.

Proteomes
2025

Discovery of a potent anti-Zika virus benzamide series targeting the viral protein NS4B.

bioRxiv : the preprint server for biology
2026

Rationalizing and mitigating the risk of live-attenuated dengue vaccines.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2025

A Review of the Changing Global Impact of Arthropod-Borne Virus Diseases and Recent Initiatives from the World Health Organization.

Medical science monitor : international medical journal of experimental and clinical research
2025

A targeted amplicon sequencing panel for cost-effective high-throughput genotyping of Aedes aegypti.

bioRxiv : the preprint server for biology
2025

The genomic diversity of arthropod-specific viruses reinforces the continental distribution pattern of Aedes aegypti.

Parasites &amp; vectors
2025

Detection of Aedes (Fredwardsius) vittatus Mosquitoes, Yucatán Peninsula, Mexico, 2025.

Emerging infectious diseases
2025

Detection and genetic diversity of Wolbachia and its associated prophage WO in mosquito populations from Ethiopia.

Scientific reports
2025

Spatial-temporal analysis of natural hazards and disasters in the Greater Horn of Africa between 2010 and 2024 to inform disaster risk reduction, and surveillance and control strategies for climate and environmentally sensitive diseases.

BMJ open
2025

Anti-NMDA receptor encephalitis following Murray Valley encephalitis: a case report.

ASM case reports
2025

Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.

The Lancet. Global health
2025

Computational approaches for designing viral protease inhibitors.

The Enzymes
2026

Neonatal tropical infections: A case series and clinical insights.

Tropical doctor
2025

Membrane-localized MET engages PVR to mediate extranuclear juvenile hormone signaling in Aedes aegypti.

Proceedings of the National Academy of Sciences of the United States of America
2025

Potential Antiviral Compounds from Hippeastrum puniceum Bulb Against Yellow Fever Virus: Bioassay-Guided Fractionation and In Silico Pharmacokinetic Analysis.

Molecules (Basel, Switzerland)
2026

Unlocking entry for yellow fever virus.

Nature reviews. Microbiology
2025

Clinical features of yellow fever in cases from Bolivia, Ecuador, Colombia, and Peru (2023-2025): A descriptive retrospective study.

New microbes and new infections
2025

Early detection of intracranial hemorrhage in Yellow Fever utilizing multimodal neuromonitoring: A case report.

Science progress
2025

Contrasted impacts of commercial diets and rearing water on Aedes aegypti fitness and microbiota.

mSphere
2024

The first mitochondrial genome of Haemagogus equinus from Jamaica.

F1000Research
2026

Coming of age: mRNA vaccines for orthoflaviviruses.

Trends in immunology
2025

Author Correction: A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicity.

Nature communications
2025

[Epidemiological situation of hepatitis E in Africa].

Virologie (Montrouge, France)
2025

Exploring the national burden and challenges in the fight against yellow fever in the Democratic Republic of Congo: a review.

Annals of medicine and surgery (2012)
2025

MRNA innovation: preparing for arboviruses and the next global outbreak.

Annals of medicine and surgery (2012)
2025

Reproductive Aging Impacts the Seminal Fluid Proteome in the Yellow Fever Mosquito, Aedes aegypti.

Proteomics
2025

Prioritization of future new vaccines introduction: The experience of the Ethiopian National Immunization Technical Advisory Group.

Vaccine
2025

Nationwide surveillance detects yellow fever and chikungunya viruses in multiple Aedes mosquito species in Nigeria.

Parasites &amp; vectors
2025

Taxonomic expansion and reorganization of Flaviviridae.

Nature microbiology
2025

Assessment of vector control strategies based on mass Aedes (Stegomyia) mosquito trapping (AGOs traps) pilot study in a US-Mexico border region of South Texas.

PLoS neglected tropical diseases
2025

Field Evaluation of Mobile Molecular Differential Tests in DRC and Nigeria.

Open forum infectious diseases
2026

Multiple LDLR family members act as entry receptors for yellow fever virus.

Nature
2025

Epidemiological situation of hepatitis E in Africa.

Virologie (Montrouge, France)
2025

In Vivo Characterization and Tissue Tropism of a Wild-Type Yellow Fever Virus Isolate from the 2017-2018 Brazilian Outbreak in C57BL/6 IFNAR1-/- Mice.

Viruses
2025

AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to Aedes Mosquito Bites in Humans.

Vaccines
2025

Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges.

Vaccines
2025

Inferring Geographic Spread of Flaviviruses Through Analysis of Hypervariable Genomic Regions.

Tropical medicine and infectious disease
2025

A new in vitro pre-clinical method for testing SARS-CoV-2 nasopharyngeal swabs.

Scientific reports
2025

The First National Record of the Invasive Mosquito Aedes vittatus (Diptera: Culicidae) in Mexico, a Threat to Public Health in Continental America.

Neotropical entomology
2026

Comparative toxicity of the isoxazolines afoxolaner, fluralaner, and fluxametamide, and the meta-diamide broflanilide against adult Aedes aegypti (Diptera: Culicidae) and Anopheles quadrimaculatus (Diptera: Culicidae).

Journal of medical entomology
2026

Population densities of black-and-gold howler monkeys (Alouatta caraya) in northeastern Argentina and the possible influence of a yellow fever outbreak.

Primates; journal of primatology
2025

Yellow Fever Vaccine-Associated Viscerotropic Disease: A Unique Case of Atraumatic Splenic Rupture.

Case reports in infectious diseases
Ver todos os 4.672 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Febre amarela.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Febre amarela

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. LRP8 is a functional receptor for yellow fever virus.
    Nature microbiology· 2026· PMID 41857414mais citado
  2. Evolution and spillover dynamics of yellow fever at the forest-urban interface in Brazil.
    Nature microbiology· 2026· PMID 41813975mais citado
  3. Dose-dependent immune modulation in arboviral coinfections among febrile patients.
    Frontiers in cellular and infection microbiology· 2026· PMID 41809986mais citado
  4. Yellow fever in Latin America and the escalating risks in a changing eco-epidemiological landscape: a review.
    Lancet regional health. Americas· 2026· PMID 41809389mais citado
  5. Spatial and social determinants of the 1857 yellow fever epidemic in Lisbon.
    PLoS neglected tropical diseases· 2026· PMID 41801989mais citado
  6. Yellow fever virus infection in non-human primates: a systematic review and meta-analysis of prevalence, seroprevalence, and epizootic case reports (1950-2025).
    Front Vet Sci· 2026· PMID 41994258recente
  7. Yellow fever vaccine.
    Dis Mon· 2026· PMID 41991420recente
  8. A targeted amplicon sequencing panel for cost-effective high-throughput genotyping of Aedes aegypti.
    Parasit Vectors· 2026· PMID 41987308recente
  9. Investigating antibody cross-reactivity and transmission dynamics of alphaviruses and flaviviruses using a multiplex serological assay.
    Nat Commun· 2026· PMID 41986360recente
  10. Preparedness for the emerging risk of yellow fever in the Americas.
    Rev Panam Salud Publica· 2026· PMID 41982848recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:99829(Orphanet)
  2. MONDO:0020502(MONDO)
  3. GARD:7914(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q154874(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Febre amarela
Compêndio · Raras BR

Febre amarela

ORPHA:99829 · MONDO:0020502
Prevalência
Unknown
CID-10
A95.0 · Febre amarela silvestre
CID-11
Ensaios
13 ativos
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0043395
Repurposing
22 candidatos
aspirincyclooxygenase inhibitor
chloramphenicolbacterial 50S ribosomal subunit inhibitor
chloramphenicol-palmitateprotein synthesis inhibitor
+17 outros
EuropePMC
Wikidata
Wikipedia
Papers 10a
Evidência
🥇 Ensaio rand.
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades